Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus-Reference-Cited by-同舟云学术

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus

Published:2022-03 Issue: Volume:163 Page:79-87
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Atkinson Victoria,Robert Caroline,Grob Jean J.^ORCID,Gogas Helen,Dutriaux Caroline,Demidov Lev,Gupta Avinash,Menzies Alexander M.,Ryll Bettina,Miranda Flora,Banerjee Hiya,Lau Mike,Del Vecchio Michele

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma;Dummer;N Engl J Med,2020

2. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial;Ascierto;Lancet Oncol,2020

3. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial;Eggermont;Ann Oncol,2020

4. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma;Long;N Engl J Med,2017

5. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma;Robert;N Engl J Med,2019

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nebenwirkungen dermatoonkologischer Therapien;Die Dermatologie;2024-05-27

2. Real‐world efficacy and safety of BRAF‐targeted therapy for patients with advanced melanoma: A single‐center retrospective study in Japan;The Journal of Dermatology;2024-05-08

3. Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy;European Journal of Cancer;2024-03

4. Exploring Advancements and Challenges in Adjuvant Melanoma Treatment;EMJ Dermatology;2024-01-30

5. Case 2-2024: A 57-Year-Old Woman with Melanoma and Fever;New England Journal of Medicine;2024-01-18